PLAINVIEW, N.Y., May 15, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional sales services, and proprietary medical products, today announced its operating results for the three months ended March 31, 2025. “The Company recorded record first quarter revenue, with revenue of $19.5 million, an increase of 3.9% when compared to the same quarter of the prior year,” commented Dr. Jun ...

Company Overview - Mobile-health Network Solutions (NASDAQ: MNDR) is a leading MedTech innovator recognized among Asia-Pacific's high-growth companies, ranked 41 in the Financial Times 2024 listing of 500 High-growth Asia-Pacific Companies [10] - The company is the first telehealth provider from the Asia-Pacific region to be listed in the US, offering personalized and reliable medical attention globally through its platform [10] Upcoming Conferences - The company will present at the Sidoti May Virtual Investor Conference on May 21-22, 2025, with presentations by co-CEOs Dr. Tung Yeng Siaw and Dr. Rachel Teoh starting at 8:30 AM ET on May 21 [2][3] - Additionally, the company will participate in the "2025 Virtual Tech Conference" hosted by Maxim Group LLC from June 3-5, 2025, with their presentation scheduled for June 4 at 8:30 AM ET [3] Conference Themes - The conferences will explore the rapid evolution of technology and its impact on various sectors, including healthcare, and how emerging growth companies are leveraging quantum computing and AI for future positioning [4]

Core Insights - The Medical sector is expected to see double-digit earnings growth in 2025, driven by strong product revenues and growing demand, despite geopolitical issues and a stronger U.S. dollar impacting costs for domestic companies [1][4]. Earnings Overview - As of April 30, 45% of Medical sector companies, representing 57.9% of the sector's market capitalization, reported earnings, with 66.7% exceeding earnings and revenue estimates. Year-over-year earnings increased by 85.2% on a revenue increase of 70.4% [3]. - First-quarter 2025 earnings for the Medical sector are projected to improve by 40% with an 8.3% sales increase, compared to 13.4% earnings growth and 9.4% revenue growth in the previous quarter [4]. MedTech Trends - The adoption of generative AI and digital therapies is enhancing patient-friendly services, driven by an aging population and increased healthcare awareness, creating new revenue opportunities for MedTech companies [5]. - Despite positive trends, challenges such as macroeconomic uncertainties, supply-chain disruptions, and labor shortages may have impacted the sector's performance [6]. Company-Specific Insights - **Fresenius Medical Care**: Expected to report revenues of $5.25 billion with an EPS estimate of 43 cents, benefiting from the FME25 transformation program, but facing challenges from high U.S. dialysis patient mortality and labor cost inflation [8][9]. - **Masimo Corporation**: Anticipated to report revenues of $367.3 million and an EPS of $1.24, supported by strong performance across major product platforms and manufacturing efficiencies [10][11]. - **Clover Health**: Projected to report revenues of $476.9 million with a loss per share estimate of 7 cents, driven by strong member retention and growth in Medicare Advantage membership, though facing near-term margin pressures due to rapid expansion [12][13].

Core Viewpoint - Mobile-health Network Solutions (MNDR) intends to acquire Lifepack, a leading pharmacy and telehealth platform in Indonesia, to expand its presence in the high-growth Indonesian healthcare market [1][2][5]. Group 1: Acquisition Details - The acquisition of Lifepack is valued at up to US$7.2 million, contingent upon Lifepack achieving its revenue target for 2025 [5]. - The consideration will be satisfied through the issuance of up to 875,000 new MNDR Class A Ordinary Shares at an issue price of US$8 per share, along with a non-refundable cash payment of US$0.2 million [5][7]. - The US$8 per share issue price represents a substantial premium to MNDR's current share price of approximately US$1.42 as of April 29, 2025, indicating the perceived value of the acquisition [5]. Group 2: Strategic Importance - The acquisition aligns with Indonesia's primary care needs and complements MNDR's telehealth expertise, aiming to serve 280 million people across 17,000 islands [2][3]. - Lifepack's platform is compliant with BPOM regulations and is positioned to lead the Indonesian digital pharmacy market, enhancing healthcare access, especially in remote areas [4][3]. - The partnership aims to create a transformative online-to-offline (O2O) healthcare platform that addresses the unique needs of Indonesia's diverse population [3][4]. Group 3: Lifepack's Operations - Lifepack operates a hybrid model delivering BPOM-licensed prescription drugs, over-the-counter medications, supplements, and medical equipment through both online and offline channels [3][9]. - The platform offers consultations with healthcare professionals via its mobile app, website, and social media, supported by an expanding warehouse network [3][9]. - Lifepack focuses on chronic disease management and preventive care, addressing the growing demand for affordable medical services in Indonesia [3][4].

Financial Data and Key Metrics Changes - In Q1 2025, the company reported revenue of $132 million, which is at the high end of the guided range, and EPS of $0.18, also at the midpoint of guidance [15][26] - Gross margins for Q1 were 48.7%, down 450 basis points year-over-year, primarily due to a supply agreement impacting margins and unfavorable customer mix [27] - Cash from operations exceeded the high end of guidance, driven by higher than expected customer prepayments, with $1 million generated in Q1 [30][32] Business Line Data and Key Metrics Changes - Medtech and specialty audio revenue was $60 million in Q1, slightly up year-over-year but seasonally down from Q4 [16][26] - Precision Device segment revenue was $73 million, flat compared to Q4, with expectations for growth as production challenges are addressed [19][20] - The company anticipates year-over-year revenue growth accelerating in Q2, supported by a strong backlog in medtech and specialty audio [18][24] Market Data and Key Metrics Changes - The company estimates that less than 5% of revenue is subject to current tariffs, with less than 3% of cost of goods sold impacted [9][10] - Inventory levels at distributors are normalizing, leading to increased order activity, particularly in the industrial market [48][75] - The medtech market is expected to remain resilient, with historical data showing modest impacts during economic downturns [12][17] Company Strategy and Development Direction - The company is focused on maintaining growth in earnings and revenue despite tariff challenges, leveraging its proximity manufacturing strategy [7][8] - There is a strong emphasis on innovation and partnerships in the medtech sector, with expectations for continued growth in 2025 [18][24] - The company is exploring acquisition opportunities and plans to maintain a manageable debt level while generating robust cash flow [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the current tariff environment with minimal impact on business [50] - The outlook for Q2 is positive, with expectations for revenue between $135 million and $145 million and EPS projected between $0.21 and $0.25 [33][34] - Management noted strong design wins and increasing backlog, indicating a solid foundation for growth in 2025 [24][78] Other Important Information - The company repurchased $5 million in shares and reduced debt by $15 million during Q1 [22][31] - The upcoming Investor Day on May 13 will provide further insights into future growth plans and competitive advantages [24][85] Q&A Session Summary Question: How is the company addressing customer exposure in uncertain times? - Management indicated that there has been no change in demand, with expectations for Q2 being higher than previously anticipated [42][44] Question: Any updates on the $75 million capacitor order for the energy market? - The company received a substantial prepayment for this order, indicating strong customer commitment and no expected delivery impacts [51][52] Question: What is the expected trajectory for gross margins in Q2 and Q4? - Management expects significant sequential improvement in gross margins, driven by increased capacity utilization and better customer mix [60][64] Question: Is there potential for gaining market share from competitors? - Management noted an increase in inquiries from customers looking for reliable supply sources, particularly in the industrial space [66][69] Question: Can you comment on bookings and receivables? - Bookings were strong, with a book-to-bill ratio above 1.15, and receivables were up due to timing of customer collections, not indicating any collection issues [73][79]

Summary of Shandong Weigao (1066.HK) Conference Call Company Overview - **Company**: Shandong Weigao (1066.HK) - **Industry**: China Healthcare Key Points and Arguments 1. **Price Target Adjustments**: - Price target increased from HK$5.20 to HK$5.90, reflecting a 13% rise in DCF-derived price target [2][6] - Bull case price target raised from HK$8.00 to HK$9.00, while bear case increased from HK$2.80 to HK$3.20 [1][2] 2. **Earnings Forecasts**: - EPS forecasts for 2025, 2026, and 2027 raised by 9%, 13%, and 12% respectively [2] - Projected sales growth of 9% YoY for 2025 and 7% YoY for 2026 [2] 3. **Growth Drivers**: - Management guidance indicates double-digit percentage growth in the medium term driven by new product launches and reduced VBP (Volume-Based Procurement) headwinds [2] - Anticipated contributions from overseas markets are expected to support growth [2] 4. **Sales Growth by Segment**: - Clinical nursing care sales growth projected at 6% for 2025, with orthopedic products expected to grow by 13.3% [18] - Interventional products sales growth forecasted at 7% for 2025 [18] 5. **Market Position**: - Shandong Weigao is recognized for having one of the most effective sales distribution networks in China, which is crucial for new product launches [12] - Despite near-term growth challenges due to price cuts and industry volume issues, the company is expected to gain market share [12] 6. **Valuation and Rating**: - Current stock rating is equal-weight, with a fair valuation against a stable growth path and dividend yield support [13] - The stock closed at HK$5.71 on April 10, 2025, with a 52-week range of HK$6.54 to HK$3.60 [3] 7. **Risks and Challenges**: - Potential risks include higher-than-expected VBP price cuts, slower volume uptake of consumables, and intense competition in pre-fillable syringes [16][22] - Regulatory headwinds and industry competition may pressure growth and margins [22] 8. **Investment Thesis**: - The investment thesis is based on a stable growth outlook with potential upside from new product contributions and favorable government policies [12][22] Additional Important Information - **DCF Methodology**: Utilized a WACC of 13.0% and a terminal growth rate of 3% for the DCF model starting from 2025 [6] - **Consensus Estimates**: The consensus price target distribution shows a mean target of HK$6.25 [7] - **Market Sentiment**: The overall industry view is considered attractive, indicating positive sentiment towards the healthcare sector in China [3][12]

Company Overview - Mobile-health Network Solutions (MNDR) is a pioneering MedTech company focused on enhancing human connection through technology [1] - The company is ranked 41 in the Financial Times 2024 listing of 500 High-growth Asia-Pacific Companies and is the first telehealth provider from the Asia-Pacific region to be listed in the US [4] - MNDR offers a range of telehealth solutions including teleconsultation services, prescription fulfillment, and personalized services such as weight management programs and gender-specific care [4] Upcoming Events - MNDR will present at the Centurion One Capital 8th Annual Growth Conference from March 3rd to March 6th, 2025, at the Four Seasons Hotel in Toronto [1][3] - Co-founders and co-CEOs, Dr. Tung Yeng Siaw and Dr. Rachel Teoh, are scheduled to present on March 6th, 2025, focusing on the company's latest AI technology innovations [2] - The presentation will include the newly deployed AI Agent platform aimed at improving healthcare providers' workflow efficiency [2] Industry Context - The telehealth solutions industry is experiencing growth, with MNDR positioned to capitalize on this trend through its innovative technology and services [4] - Centurion One Capital, the investment banking firm hosting the conference, is dedicated to supporting the growth of companies in North America, indicating a favorable environment for investment in the sector [5][6]